NCT03810807 2025-12-23
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
13 trialsNCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT04027647 2025-06-12
Phase 2 Study of Dacomitinib in NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT04946968 2025-06-11
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT06486142 2024-07-03
ERIS
Region Skane
Phase 3 Recruiting
NCT05271916 2023-04-19
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT04811001 2023-02-21
CAPLAND
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT04768491 2021-02-24
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Peking Union Medical College
Unknown
NCT04675008 2021-01-05
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
Phase 2 Unknown
NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
NCT04339829 2020-04-09
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT01918761 2019-12-30
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Central European Cooperative Oncology Group
Phase 1 Terminated